Pharmaceutical corporation Celgene acquired $15m worth of series B2 stock in US-based small molecule drug company Acetylon Pharmaceuticals on Thursday. Celgene will not however, hold licensing or marketing rights to drugs currently under development at Acetylon.

Acetylon closed its series B round in June having raised $27m, while its series A round raised $9.25m over two separate tranches. Acetylon has not disclosed the identity of its private equity investors but they are thought to include holding company the Kraft Group.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?